MISSISSAUGA, Ontario– MedX Health Corp. (TSXV: MDX), a global leader in teledermatology and non-invasive skin analysis, has appointed Dr. Symon D. Cotton as Strategic Advisor to support the company’s artificial intelligence and product development initiatives.
Dr. Cotton, an accomplished medical device innovator and co-developer of SIAscopy, currently serves as Head of Life Sciences at a leading technology organization. His career has focused on integrating engineering, biology, and computation, helping companies develop advanced medical devices and digital health platforms.
As one of the key architects of Spectrophotometric Intracutaneous Analysis (SIAscopy), Dr. Cotton worked alongside Dr. Paul Matts to create the first technology capable of simultaneously and non-invasively measuring melanin, hemoglobin, and collagen within the skin. This innovation laid the foundation for SIAscopy’s adoption in dermatology and its integration into MedX’s DermSecure platform.
Dr. Cotton also brings expertise in AI-driven analytics for medical imaging and diagnostics, a focus directly aligned with MedX’s growth strategy. His background in computational biology, device design, and translational medicine will help MedX further develop AI models trained on SIAscopy’s imaging datasets to enhance diagnostic accuracy and scalability.
“I am proud to have been part of the original SIAscopy journey and excited to rejoin the field with MedX at such a pivotal moment,” said Dr. Cotton. “With AI poised to transform teledermatology, I look forward to helping MedX leverage its unmatched imaging database and DermSecure platform to improve early skin cancer detection worldwide.”
MedX CEO John Gevisser welcomed the appointment, noting Dr. Cotton’s historic role and future contributions. “Dr. Cotton’s contribution to SIAscopy was instrumental in shaping the technology that underpins MedX’s global teledermatology platform today. His expertise in medical device innovation and AI strategy will help us extend our leadership at the forefront of skin optics and machine learning, ensuring MedX solutions remain both clinically rigorous and commercially scalable.”
